3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers
Enrollment expected to start in early Q1 2022
Read more at globenewswire.comTrevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
